Loading...

Steven Barriere, PharmD

TitleClinical Professor
SchoolUCSF School of Pharmacy
DepartmentClinical Pharmacy
Address533 Parnassus Avenue
San Francisco CA 94117
Phone415-476-2352
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoPharm.D.1973 Pharmacy

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Smart JI, Corey GR, Stryjewski ME, Wang W, Barriere S. Assessment of telavancin minimal inhibitory concentrations by revised broth microdilution method in phase 3 complicated skin and skin-structure infection clinical trial isolates. Diagn Microbiol Infect Dis. 2016 Dec 14. PMID: 28038840.
      View in: PubMed
    2. Smart JI, Corey GR, Stryjewski ME, Wang W, Barriere S. Assessment of Minimum Inhibitory Concentrations of Telavancin by Revised Broth Microdilution Method in Phase 3 Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia Clinical Isolates. Infect Dis Ther. 2016 Oct 7. PMID: 27718118.
      View in: PubMed
    3. Lacy MK, Stryjewski ME, Wang W, Hardin TC, Nogid B, Luke DR, Shorr AF, Corey GR, Barriere S. Telavancin hospital-acquired pneumonia trials: impact of Gram-negative infections and inadequate Gram-negative coverage on clinical efficacy and all-cause mortality. Clin Infect Dis. 2015 Sep 15; 61 Suppl 2:S87-93. PMID: 26316562.
      View in: PubMed
    4. Pushkin R, Barriere S, Wang W, Corey GR, Stryjewski ME. Telavancin for Acute Bacterial Skin and Skin Structure Infections, a Post Hoc Analysis of the Phase 3 ATLAS Trials in Light of the 2013 FDA Guidance. Antimicrob Agents Chemother. 2015 Oct; 59(10):6170-4. PMID: 26248356; PMCID: PMC4576104.
      View in: PubMed, PubMed Central
    5. Worboys PD, Wong SL, Barriere S. Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment. Eur J Clin Pharmacol. 2015 Jun; 71(6):707-14. PMID: 25939708; PMCID: PMC4430595.
      View in: PubMed, PubMed Central
    6. Barriere S. Clinical, economic and societal impact of antibiotic resistance. Expert Opin Pharmacother. 2015 Feb; 16(2):151-3. PMID: 25483564.
      View in: PubMed
    7. Corey GR, Rubinstein E, Stryjewski ME, Bassetti M, Barriere S. Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus. Clin Infect Dis. 2015 Mar 1; 60(5):787-96. PMID: 25472944; PMCID: PMC4329924.
      View in: PubMed, PubMed Central
    8. McConeghy KW, Liao S, Clark D, Worboys P, Barriere S, Rodvold KA. Variability in telavancin cross-reactivity among vancomycin immunoassays. Antimicrob Agents Chemother. 2014 Dec; 58(12):7093-7. PMID: 25223996; PMCID: PMC4249549.
      View in: PubMed, PubMed Central
    9. Barriere S, Farrell DJ, Rhomberg PR, Jones RN. Serum inhibitory and bactericidal activity of telavancin in non-infected subjects with severe renal impairment or end-stage renal disease. Diagn Microbiol Infect Dis. 2014 Dec; 80(4):327-9. PMID: 25306423.
      View in: PubMed
    10. Stryjewski ME, Lentnek A, O'Riordan W, Pullman J, Tambyah PA, Miró JM, Fowler VG, Barriere S, Kitt MM, Corey GR. A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study. BMC Infect Dis. 2014; 14:289. PMID: 24884578; PMCID: PMC4048626.
      View in: PubMed, PubMed Central
    11. Rubinstein E, Stryjewski ME, Barriere S. Clinical utility of telavancin for treatment of hospital-acquired pneumonia: focus on non-ventilator-associated pneumonia. Infect Drug Resist. 2014; 7:129-35. PMID: 24876786; PMCID: PMC4035308.
      View in: PubMed, PubMed Central
    12. Barriere S, Stryjewski ME, Corey GR, Genter FC, Rubinstein E. Effect of vancomycin serum trough levels on outcomes in patients with nosocomial pneumonia due to Staphylococcus aureus: a retrospective, post hoc, subgroup analysis of the Phase 3 ATTAIN studies. BMC Infect Dis. 2014; 14:183. PMID: 24708675; PMCID: PMC4101862.
      View in: PubMed, PubMed Central
    13. Barriere S. The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia. Future Microbiol. 2014; 9(3):281-9. PMID: 24450506.
      View in: PubMed
    14. Corey GR, Kollef MH, Shorr AF, Rubinstein E, Stryjewski ME, Hopkins A, Barriere S. Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival. Antimicrob Agents Chemother. 2014; 58(4):2030-7. PMID: 24419353; PMCID: PMC4023742.
      View in: PubMed, PubMed Central
    15. Torres A, Rubinstein E, Corey GR, Stryjewski ME, Barriere S. Analysis of Phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure. J Antimicrob Chemother. 2014 Apr; 69(4):1119-26. PMID: 24398339; PMCID: PMC4023300.
      View in: PubMed, PubMed Central
    16. Ero MP, Harvey NR, Harbert JL, Janc JW, Chin KH, Barriere S. Impact of telavancin on prothrombin time and activated partial thromboplastin time as determined using point-of-care coagulometers. J Thromb Thrombolysis. 2014; 38(2):235-40. PMID: 24132401.
      View in: PubMed
    17. Stryjewski ME, Barriere S, Rubinstein E, Genter FC, Lentnek AL, Magana-Aquino M, Luna CM, Niederman MS, Torres A, Corey GR. Telavancin versus vancomycin for bacteraemic hospital-acquired pneumonia. Int J Antimicrob Agents. 2013 Oct; 42(4):367-9. PMID: 23891527.
      View in: PubMed
    18. Krause KM, Blais J, Lewis SR, Lunde CS, Barriere S, Friedland HD, Kitt MM, Benton BM. In vitro activity of telavancin and occurrence of vancomycin heteroresistance in isolates from patients enrolled in phase 3 clinical trials of hospital-acquired pneumonia. Diagn Microbiol Infect Dis. 2012 Dec; 74(4):429-31. PMID: 23083812.
      View in: PubMed
    19. Stryjewski ME, Potgieter PD, Li YP, Barriere S, Churukian A, Kingsley J, Corey GR. TD-1792 versus vancomycin for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother. 2012 Nov; 56(11):5476-83. PMID: 22869571; PMCID: PMC3486540.
      View in: PubMed, PubMed Central
    20. Stryjewski ME, Barriere S, O'Riordan W, Dunbar LM, Hopkins A, Genter FC, Corey GR. Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections. J Antimicrob Chemother. 2012 Jun; 67(6):1496-502. PMID: 22416054.
      View in: PubMed
    21. Samara E, Shaw JP, Barriere S, Wong SL, Worboys P. Population pharmacokinetics of telavancin in healthy subjects and patients with infections. Antimicrob Agents Chemother. 2012 Apr; 56(4):2067-73. PMID: 22252798; PMCID: PMC3318396.
      View in: PubMed, PubMed Central
    22. Lodise TP, Butterfield JM, Hegde SS, Samara E, Barriere S. Telavancin pharmacokinetics and pharmacodynamics in patients with complicated skin and skin structure infections and various degrees of renal function. Antimicrob Agents Chemother. 2012 Apr; 56(4):2062-6. PMID: 22252799; PMCID: PMC3318336.
      View in: PubMed, PubMed Central
    23. Sharma-Kuinkel BK, Ahn SH, Rude TH, Zhang Y, Tong SY, Ruffin F, Genter FC, Braughton KR, Deleo FR, Barriere S, Fowler VG. Presence of genes encoding panton-valentine leukocidin is not the primary determinant of outcome in patients with hospital-acquired pneumonia due to Staphylococcus aureus. J Clin Microbiol. 2012 Mar; 50(3):848-56. PMID: 22205797; PMCID: PMC3295120.
      View in: PubMed, PubMed Central
    24. Nienaber JJ, Sharma Kuinkel BK, Clarke-Pearson M, Lamlertthon S, Park L, Rude TH, Barriere S, Woods CW, Chu VH, Marín M, Bukovski S, Garcia P, Corey GR, Korman T, Doco-Lecompte T, Murdoch DR, Reller LB, Fowler VG. Methicillin-susceptible Staphylococcus aureus endocarditis isolates are associated with clonal complex 30 genotype and a distinct repertoire of enterotoxins and adhesins. J Infect Dis. 2011 Sep 1; 204(5):704-13. PMID: 21844296; PMCID: PMC3156104.
      View in: PubMed, PubMed Central
    25. Barriere S, Goldberg MR, Janc JW, Higgins DL, Macy PA, Adcock DM. Effects of telavancin on coagulation test results. Int J Clin Pract. 2011 Jul; 65(7):784-9. PMID: 21564449.
      View in: PubMed
    26. Rubinstein E, Lalani T, Corey GR, Kanafani ZA, Nannini EC, Rocha MG, Rahav G, Niederman MS, Kollef MH, Shorr AF, Lee PC, Lentnek AL, Luna CM, Fagon JY, Torres A, Kitt MM, Genter FC, Barriere S, Friedland HD, Stryjewski ME. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis. 2011 Jan 1; 52(1):31-40. PMID: 21148517; PMCID: PMC3060890.
      View in: PubMed, PubMed Central
    27. Barriere S. ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections. Future Microbiol. 2010 Dec; 5(12):1765-73. PMID: 21080861.
      View in: PubMed
    28. Krause KM, Barriere S, Kitt MM, Benton BM. In vitro activity of telavancin against Gram-positive isolates from complicated skin and skin structure infections: results from 2 phase 3 (ATLAS) clinical studies. Diagn Microbiol Infect Dis. 2010 Oct; 68(2):181-5. PMID: 20846593.
      View in: PubMed
    29. Goldberg MR, Wong SL, Shaw JP, Kitt MM, Barriere S. Single-dose pharmacokinetics and tolerability of telavancin in elderly men and women. Pharmacotherapy. 2010 Aug; 30(8):806-11. PMID: 20653356.
      View in: PubMed
    30. Barriere S. Challenges in the design and conduct of clinical trials for hospital-acquired pneumonia and ventilator-associated pneumonia: an industry perspective. Clin Infect Dis. 2010 Aug 1; 51 Suppl 1:S4-9. PMID: 20597670.
      View in: PubMed
    31. Wong SL, Goldberg MR, Ballow CH, Kitt MM, Barriere S. Effect of Telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects. Pharmacotherapy. 2010 Feb; 30(2):136-43. PMID: 20099988.
      View in: PubMed
    32. Goldberg MR, Wong SL, Shaw JP, Kitt MM, Barriere S. Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin. Pharmacotherapy. 2010 Jan; 30(1):35-42. PMID: 20030471.
      View in: PubMed
    33. Bae IG, Tonthat GT, Stryjewski ME, Rude TH, Reilly LF, Barriere S, Genter FC, Corey GR, Fowler VG. Presence of genes encoding the panton-valentine leukocidin exotoxin is not the primary determinant of outcome in patients with complicated skin and skin structure infections due to methicillin-resistant Staphylococcus aureus: results of a multinational trial. J Clin Microbiol. 2009 Dec; 47(12):3952-7. PMID: 19846653; PMCID: PMC2786648.
      View in: PubMed, PubMed Central
    34. Patel JH, Churchwell MD, Seroogy JD, Barriere S, Grio M, Mueller B. Telavancin and hydroxy propyl-beta-cyclodextrin clearance during continuous renal replacement therapy: an in vitro study. Int J Artif Organs. 2009 Oct; 32(10):745-51. PMID: 19943236.
      View in: PubMed
    35. Wong SL, Sörgel F, Kinzig M, Goldberg MR, Kitt MM, Barriere S. Lack of pharmacokinetic drug interactions following concomitant administration of telavancin with aztreonam or piperacillin/tazobactam in healthy participants. J Clin Pharmacol. 2009 Jul; 49(7):816-23. PMID: 19443680.
      View in: PubMed
    36. Wilson SE, O'Riordan W, Hopkins A, Friedland HD, Barriere S, Kitt MM. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures. Am J Surg. 2009 Jun; 197(6):791-6. PMID: 19095213.
      View in: PubMed
    37. Laohavaleeson S, Barriere S, Nicolau DP, Kuti JL. Cost-effectiveness of telavancin versus vancomycin for treatment of complicated skin and skin structure infections. Pharmacotherapy. 2008 Dec; 28(12):1471-82. PMID: 19025428.
      View in: PubMed
    38. Wong SL, Barriere S, Kitt MM, Goldberg MR. Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. J Antimicrob Chemother. 2008 Oct; 62(4):780-3. PMID: 18586659.
      View in: PubMed
    39. Stryjewski ME, Graham DR, Wilson SE, O'Riordan W, Young D, Lentnek A, Ross DP, Fowler VG, Hopkins A, Friedland HD, Barriere S, Kitt MM, Corey GR. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis. 2008 Jun 1; 46(11):1683-93. PMID: 18444791.
      View in: PubMed
    40. Lodise TP, Gotfried M, Barriere S, Drusano GL. Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother. 2008 Jul; 52(7):2300-4. PMID: 18426898; PMCID: PMC2443895.
      View in: PubMed, PubMed Central
    41. Campbell SJ, Deshmukh HS, Nelson CL, Bae IG, Stryjewski ME, Federspiel JJ, Tonthat GT, Rude TH, Barriere S, Corey R, Fowler VG. Genotypic characteristics of Staphylococcus aureus isolates from a multinational trial of complicated skin and skin structure infections. J Clin Microbiol. 2008 Feb; 46(2):678-84. PMID: 18077636; PMCID: PMC2238106.
      View in: PubMed, PubMed Central
    42. Gotfried MH, Shaw JP, Benton BM, Krause KM, Goldberg MR, Kitt MM, Barriere S. Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics. Antimicrob Agents Chemother. 2008 Jan; 52(1):92-7. PMID: 17923490; PMCID: PMC2223919.
      View in: PubMed, PubMed Central
    43. Stryjewski ME, Chu VH, O'Riordan WD, Warren BL, Dunbar LM, Young DM, Vallée M, Fowler VG, Morganroth J, Barriere S, Kitt MM, Corey GR. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother. 2006 Mar; 50(3):862-7. PMID: 16495243; PMCID: PMC1426424.
      View in: PubMed, PubMed Central
    44. Stryjewski ME, O'Riordan WD, Lau WK, Pien FD, Dunbar LM, Vallee M, Fowler VG, Chu VH, Spencer E, Barriere S, Kitt MM, Cabell CH, Corey GR. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis. 2005 Jun 1; 40(11):1601-7. PMID: 15889357.
      View in: PubMed
    45. Shaw JP, Seroogy J, Kaniga K, Higgins DL, Kitt M, Barriere S. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother. 2005 Jan; 49(1):195-201. PMID: 15616296; PMCID: PMC538848.
      View in: PubMed, PubMed Central
    46. Barriere S, Genter F, Spencer E, Kitt M, Hoelscher D, Morganroth J. Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J Clin Pharmacol. 2004 Jul; 44(7):689-95. PMID: 15199073.
      View in: PubMed
    47. Nichols RL, Graham DR, Barriere S, Rodgers A, Wilson SE, Zervos M, Dunn DL, Kreter B. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group. J Antimicrob Chemother. 1999 Aug; 44(2):263-73. PMID: 10473234.
      View in: PubMed
    48. Jaresko GS, Barriere S, Johnson BL. Serum and blister fluid pharmacokinetics and bactericidal activities of ampicillin-sulbactam, cefotetan, cefoxitin, ceftizoxime, and ticarcillin-clavulanate. Antimicrob Agents Chemother. 1992 Oct; 36(10):2233-8. PMID: 1444304; PMCID: PMC245482.
      View in: PubMed, PubMed Central
    49. Barriere S. Pharmacology and pharmacokinetics of cefprozil. Clin Infect Dis. 1992 Jun; 14 Suppl 2:S184-8; discussion S195-6. PMID: 1617036.
      View in: PubMed
    50. Barriere S, Guglielmo BJ. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies. Clin Pharm. 1992 Mar; 11(3):223-35. PMID: 1611812.
      View in: PubMed
    51. Kalman D, Barriere S, Johnson BL. Pharmacokinetic disposition and bactericidal activities of cefepime, ceftazidime, and cefoperazone in serum and blister fluid. Antimicrob Agents Chemother. 1992 Feb; 36(2):453-7. PMID: 1605609; PMCID: PMC188456.
      View in: PubMed, PubMed Central
    52. Kaatz GW, Seo SM, Barriere S, Albrecht LM, Rybak MJ. Development of resistance to fleroxacin during therapy of experimental methicillin-susceptible Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1991 Aug; 35(8):1547-50. PMID: 1929325; PMCID: PMC245216.
      View in: PubMed, PubMed Central
    53. Kalman D, Barriere S. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis. 1991 Jan; 163(1):201-3. PMID: 1984470.
      View in: PubMed
    54. Barriere S. Monotherapy versus combination antimicrobial therapy: a review. Pharmacotherapy. 1991; 11(2 ( Pt 2)):64S-71S. PMID: 2041834.
      View in: PubMed
    55. Barriere S, Catlin DH, Orlando PL, Noe A, Frost RW. Alteration in the pharmacokinetic disposition of ciprofloxacin by simultaneous administration of azlocillin. Antimicrob Agents Chemother. 1990 May; 34(5):823-6. PMID: 2360821; PMCID: PMC171699.
      View in: PubMed, PubMed Central
    56. Orlando PL, Barriere S, Hindler JA, Frost RW. Serum bactericidal activity from intravenous ciprofloxacin and azlocillin given alone and in combination to healthy subjects. Diagn Microbiol Infect Dis. 1990 Mar-Apr; 13(2):93-7. PMID: 2114954.
      View in: PubMed
    57. Kaatz GW, Seo SM, Barriere S, Albrecht LM, Rybak MJ. Efficacy of ofloxacin in experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1990 Feb; 34(2):257-60. PMID: 2327773; PMCID: PMC171568.
      View in: PubMed, PubMed Central
    58. Kaatz GW, Seo SM, Barriere S, Albrecht LM, Rybak MJ. Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1989 Aug; 33(8):1184-7. PMID: 2802547; PMCID: PMC172621.
      View in: PubMed, PubMed Central
    59. Rodondi LC, Flaherty JF, Schoenfeld P, Barriere S, Gambertoglio JG. Influence of coadministration on the pharmacokinetics of mezlocillin and cefotaxime in healthy volunteers and in patients with renal failure. Clin Pharmacol Ther. 1989 May; 45(5):527-34. PMID: 2721108.
      View in: PubMed
    60. Kaatz GW, Seo SM, Barriere S, Albrecht LM, Rybak MJ. Efficacy of fleroxacin in experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1989 Apr; 33(4):519-21. PMID: 2499251; PMCID: PMC172471.
      View in: PubMed, PubMed Central
    61. Barriere S, Kaatz GW, Seo SM. Enhanced elimination of ciprofloxacin after multiple-dose administration of rifampin to rabbits. Antimicrob Agents Chemother. 1989 Apr; 33(4):589-90. PMID: 2729952; PMCID: PMC172487.
      View in: PubMed, PubMed Central
    62. Moore ES, Jimenez M, Barriere S, Cimino ML, Fekety FR. Additive and synergistic bactericidal activity contributed by desacetylcefotaxime during cefotaxime therapy. Clin Pharm. 1988 Dec; 7(12):901-5. PMID: 3208502.
      View in: PubMed
    63. Lam YW, Duroux MH, Gambertoglio JG, Barriere S, Guglielmo BJ. Effect of protein binding on serum bactericidal activities of ceftazidime and cefoperazone in healthy volunteers. Antimicrob Agents Chemother. 1988 Mar; 32(3):298-302. PMID: 3284457; PMCID: PMC172163.
      View in: PubMed, PubMed Central
    64. Kaatz GW, Barriere S, Schaberg DR, Fekety R. The emergence of resistance to ciprofloxacin during treatment of experimental Staphylococcus aureus endocarditis. J Antimicrob Chemother. 1987 Nov; 20(5):753-8. PMID: 3429376.
      View in: PubMed
    65. Barriere S, Kaatz GW, Schaberg DR, Fekety R. Altered pharmacokinetic disposition of ciprofloxacin and vancomycin after single and multiple doses in rabbits. Antimicrob Agents Chemother. 1987 Jul; 31(7):1075-8. PMID: 3662471; PMCID: PMC174874.
      View in: PubMed, PubMed Central
    66. Flaherty JF, Barriere S, Mordenti J, Gambertoglio JG. Effect of dose on pharmacokinetics and serum bactericidal activity of mezlocillin. Antimicrob Agents Chemother. 1987 Jun; 31(6):895-8. PMID: 3619421; PMCID: PMC284206.
      View in: PubMed, PubMed Central
    67. Kaatz GW, Barriere S, Schaberg DR, Fekety R. Ciprofloxacin versus vancomycin in the therapy of experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1987 Apr; 31(4):527-30. PMID: 3649202; PMCID: PMC174771.
      View in: PubMed, PubMed Central
    68. Guglielmo BJ, Flaherty JF, Batman R, Barriere S, Gambertoglio JG. Comparative pharmacokinetics of low- and high-dose ticarcillin. Antimicrob Agents Chemother. 1986 Sep; 30(3):359-60. PMID: 3777901; PMCID: PMC180559.
      View in: PubMed, PubMed Central
    69. Barriere S, Ozasa DC, Mordenti J. Assessment of serum bactericidal activity after administration of cefoperazone, cefotaxime, ceftizoxime, and moxalactam to healthy subjects. Antimicrob Agents Chemother. 1985 Jul; 28(1):55-7. PMID: 3929680; PMCID: PMC176309.
      View in: PubMed, PubMed Central
    70. Barriere S, Ely E, Kapusnik JE, Gambertoglio JG. Analysis of a new method for assessing activity of combinations of antimicrobials: area under the bactericidal activity curve. J Antimicrob Chemother. 1985 Jul; 16(1):49-59. PMID: 3930461.
      View in: PubMed
    71. Gambertoglio JG, Alexander DP, Barriere S. Cefmenoxime pharmacokinetics in healthy volunteers and subjects with renal insufficiency and on hemodialysis. Antimicrob Agents Chemother. 1984 Dec; 26(6):845-9. PMID: 6098220; PMCID: PMC180037.
      View in: PubMed, PubMed Central
    72. Barriere S, Gambertoglio JG, Alexander DP, Stagg RJ, Conte JE. Pharmacokinetic disposition of cefonicid in patients with renal failure and receiving hemodialysis. Rev Infect Dis. 1984 Nov-Dec; 6 Suppl 4:S809-15. PMID: 6522922.
      View in: PubMed
    73. Barriere S, Flaherty JF. Third-generation cephalosporins: a critical evaluation. Clin Pharm. 1984 Jul-Aug; 3(4):351-73. PMID: 6432420.
      View in: PubMed
    74. Gambertoglio JG, Barriere S, Lin ET, Conte JE. Amdinocillin pharmacokinetics. Simultaneous administration with cephalothin and cerebrospinal fluid penetration. Am J Med. 1983 Aug 29; 75(2A):54-9. PMID: 6311006.
      View in: PubMed
    75. Noonan IA, Gambertoglio JG, Barriere S, Conte JE, Lin ET. High-performance liquid chromatographic determination of cefmenoxime (AB-50912) in human plasma and urine. J Chromatogr. 1983 Apr 8; 273(2):458-63. PMID: 6306028.
      View in: PubMed
    76. Barriere S, Hatheway GJ, Gambertoglio JG, Lin ET, Conte JE. Pharmacokinetics of cefonicid, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1982 Jun; 21(6):935-8. PMID: 7114840; PMCID: PMC182048.
      View in: PubMed, PubMed Central
    77. Barriere S, Gambertoglio JG, Lin ET, Conte JE. Multiple-dose pharmacokinetics of amdinocillin in healthy volunteers. Antimicrob Agents Chemother. 1982 Jan; 21(1):54-7. PMID: 6282208; PMCID: PMC181828.
      View in: PubMed, PubMed Central
    78. King CY, Barriere S. Analysis of the in vitro interaction between vancomycin and cholestyramine. Antimicrob Agents Chemother. 1981 Feb; 19(2):326-7. PMID: 6812491; PMCID: PMC181420.
      View in: PubMed, PubMed Central
    79. Gambertoglio JG, Barriere S, Lin ET, Conte JE. Pharmacokinetics of mecillinam in health subjects. Antimicrob Agents Chemother. 1980 Dec; 18(6):952-6. PMID: 6263180; PMCID: PMC352996.
      View in: PubMed, PubMed Central
    Steven's Networks
    Concepts
    Derived automatically from this person's publications.
    See all (240) concept(s)
    _
    Co-Authors
    People in Profiles who have published with this person.
    See all (2) people
    _
    Related Authors
    People who share related concepts with this person.
    See all (60) people
    _
    Back to TOP